Marco Valgimigli

Marco Valgimigli, M .D., Ph.D., Enrico Frigoli, M.D., Sergio Leonardi, M.D., M.H.S.Sc., Andrea Gagnor, M.D.D., Ph.D., Stefano Garducci, M.D., Paolo Rubartelli, M.D., Carlo Briguori, M.D.D., Ph.D., Alessandra Repetto, M.D., Ugo Limbruno, M.D., Roberto Garbo, M.D., Paolo Sganzerla, M.D., Filippo Russo, M.D., Alessandro Lupi, M.D., Bernardo Cortese, M.D., Arturo Ausiello, M.D., Salvatore Ierna, M.D., Giovanni Esposito, M.D., Ph.D., Patrizia Presbitero, M.D., Andrea Santarelli, M.D., Gennaro Sardella, M.D., Ferdinando Varbella, M.D., Simone Tresoldi, M.D., Nicoletta de Cesare, M.D., Stefano Rigattieri, M.D., Ph.D., Antonio Zingarelli, M.D., Paolo Tosi, M.D.D., Ph.D., Giacomo Boccuzzi, M.D., Elmir Omerovic, M.D., Ph.D.D., Ph.D., Dik Heg, Ph.D.D., and Pascal Vranckx, M.D., Ph.D.

IN-MAY 2013, the medical development of pritelivir was positioned on hold by the Food and Drug Administration because of unexplained dermal and hematologic findings in a toxicology study of monkeys treated with daily doses ranging from 75 mg per kilogram of bodyweight to 1000 mg per kilogram . The reason behind the findings in monkeys is under investigation currently; such findings weren’t observed in the current trial.. Anna Wald, M.D., M.P.H., Lawrence Corey, M.D., Burkhard Timmler, M.D., Amalia Magaret, Ph.D., Terri Warren, M.N., Stephen Tyring, M.D., Ph.D., Christine Johnston, M.D., M.P.H., John Kriesel, M.D., Kenneth Fife, M.D., Ph.D., Lawrence Galitz, M.D., Susanne Stoelben, M.D., M.P.H., Meei-Li Huang, Ph.D., Stacy Selke, M.A., Hans-Peter Stobernack, D.V.M., Helga Ruebsamen-Schaeff, Ph.D., and Alexander Birkmann, Ph.D.1 These compounds, that have been developed three decades ago and are in widespread use today, ameliorate clinical disease.